01—Abstract
Summary
Summary of the 8-K filed October 21, 2026. Cited figures are marked; the original filing is the authoritative source.
Roivant Sciences Ltd. (ROIV) reported, via a press release furnished as Exhibit 99.1 to this Form 8-K, positive results from the Phase 3 CLARITY-1 and CLARITY-2 trials evaluating brepocitinib 45 mg once daily in non-infectious uveitis (NIU).
The trials were conducted by its subsidiary Priovant Therapeutics, Inc. Brepocitinib achieved statistically significant benefit versus placebo on the primary endpoint (time to treatment failure) and all key secondary endpoints in both studies. Median time to treatment failure was greater than 48 weeks in both studies versus about 12 weeks on placebo (p<0.0001 in both). Pooled across the studies, 62%a of brepocitinib patients achieved steroid-free quiescence at Week 48 versus 20% on placebo.
The filing reports that 42%b of eyes on brepocitinib achieved resolution of macular edema at Week 48 versus 4.8% on placebo (pooled, among patients with macular edema at baseline). Safety was described as consistent with prior brepocitinib trials with no new safety signals, and only 3% of participants discontinued treatment due to an adverse event. Priovant intends to file a supplemental New Drug Application for NIU in the first half of calendar 2027.
The company also plans an investor call on October 21, 2026 and an investor day on December 9, 2026. The company describes brepocitinib, already approved as LISRAYA for adult dermatomyositis, as potentially the most effective systemic, non-steroid treatment option for NIU. Management's characterization of the results as a potential new standard of care is company-generated and the filing does not provide regulatory review outcomes or commercial projections.
02—Key points
Key Highlights
- Phase 3 CLARITY-1 (N=166) and CLARITY-2 (N=204) both met the primary endpoint of time to treatment failure, with hazard ratios of 0.27 and 0.22 versus placebo (P<0.0001 in both).
- Cumulative incidence of treatment failure at Week 48 was 35.4% (CLARITY-1) and 32.4% (CLARITY-2) for brepocitinib, versus 78.7% and 77.8% on placebo.
- Steroid-free quiescence in both eyes at Week 48 was 58.8% and 64.4% on brepocitinib versus 19.8% and 19.4% on placebo; pooled, 62% versus 20% (P<0.0001).
- Resolution of macular edema at Week 48 was 42% pooled on brepocitinib versus 4.8% on placebo, with 40.4% vs. 2.1% in CLARITY-1 and 42.6% vs. 7.0% in CLARITY-2.
- Brepocitinib also achieved statistically significant benefit on chorioretinal vascular leakage (FA response) and patient-reported visual functioning (NEI VFQ-25) endpoints in both trials.
- Safety was consistent with the known profile of brepocitinib with no new safety signals; 3% of participants discontinued treatment due to an adverse event.
- Priovant plans to file an sNDA for brepocitinib in NIU in the first half of calendar 2027; Roivant will hold an investor call on October 21, 2026 and an investor day on December 9, 2026.
03—Questions
Frequently Asked Questions
What did the CLARITY program study and what was the primary endpoint?
The CLARITY program comprised two identical Phase 3 trials (CLARITY-1 and CLARITY-2) enrolling 371 patients with non-infectious uveitis. Patients were randomized 1:1 to once-daily brepocitinib 45 mg or placebo for a 48-week double-masked treatment period, after an 8-week oral corticosteroid regimen with a mandatory taper to zero. The primary endpoint was time to treatment failure, assessed from Week 6 through Week 48.
How large was the treatment benefit on the primary endpoint?
Median time to treatment failure was greater than 48 weeks for brepocitinib in both studies, compared with about 12 weeks on placebo in each (p<0.0001 in both). Hazard ratios versus placebo were 0.27 (95% CI 0.17–0.43) in CLARITY-1 and 0.22 (95% CI 0.14–0.34) in CLARITY-2.
Were the safety results acceptable?
The filing states that brepocitinib was generally well tolerated, most events were mild or moderate, and only 3% of participants discontinued treatment due to an adverse event. The company reports the safety profile was consistent with brepocitinib's known profile with no new safety signals.
What are the next regulatory and corporate steps?
Priovant Therapeutics intends to file a supplemental New Drug Application for brepocitinib for NIU in the first half of calendar year 2027. Roivant scheduled an investor call on October 21, 2026 at 8:00 a.m. ET to discuss the results and will host an investor day on December 9, 2026.
What is the commercial context for brepocitinib?
According to the filing, brepocitinib is marketed as LISRAYA, which is commercially available for adults with dermatomyositis and is the first and only targeted oral therapy approved for that indication. NIU would be a potential additional indication, while cutaneous sarcoidosis and lichen planopilaris remain under evaluation and have not been approved by the FDA.
04—Continue